How has BridgeBio Pharma's cash and cash equivalents, end of period changed year-over-year?

BridgeBio Pharma's cash and cash equivalents, end of period increased by 62.5% year-over-year, from $542.74M to $882.02M.

What is the long-term trend for BridgeBio Pharma's cash and cash equivalents, end of period?

Over 2 years (2023 to 2025), BridgeBio Pharma's cash and cash equivalents, end of period has grown at a 20.4% compound annual growth rate (CAGR), from $394.73M to $572.14M.

BridgeBio Pharma BBIO Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's cash and cash equivalents, end of period?: BridgeBio Pharma (BBIO) reported cash and cash equivalents, end of period of $882.02M in Q1 2026.
How has BridgeBio Pharma's cash and cash equivalents, end of period changed year-over-year?: BridgeBio Pharma's cash and cash equivalents, end of period increased by 62.5% year-over-year, from $542.74M to $882.02M.
What is the long-term trend for BridgeBio Pharma's cash and cash equivalents, end of period?: Over 2 years (2023 to 2025), BridgeBio Pharma's cash and cash equivalents, end of period has grown at a 20.4% compound annual growth rate (CAGR), from $394.73M to $572.14M.